Plasma Aβ42/Aβ40 measured by immunoprecipitation mass spectrometry (IPMS) can be used to screen cognitively normal people for amyloidosis accurately.
Why this matters
Amyloid positron emission tomography (PET) scans and cerebrospinal fluid (CSF) tests for Aβ42 and Aβ40 are validated biomarkers for people with Alzheimer’s disease (AD), however, these methods are costly and invasive.
An accurate blood test for an AD biomarker would be inexpensive, quick, and useful for preventative clinical trials, however, this is not available.
Möchten Sie mehr lesen?
Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.
Sie haben bereits einen Account? Einloggen
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.